discussion outline

47

Upload: genevieve-robert

Post on 31-Dec-2015

24 views

Category:

Documents


0 download

DESCRIPTION

Discussion Outline. Cells of the Immune System. Innate Immunity. Receptors on T and B Cells Are Specific for Each Antigen. Innate and Adaptive Immune Systems. Antigen Presentation. Adaptive Immunity. Function of the Immune System. Tumor Escape Mechanisms. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Discussion Outline
Page 2: Discussion Outline
Page 3: Discussion Outline
Page 4: Discussion Outline

Discussion Outline

Page 5: Discussion Outline

Cells of the Immune System

Page 6: Discussion Outline

Innate Immunity

Page 7: Discussion Outline

Receptors on T and B Cells Are Specific for Each Antigen

Page 8: Discussion Outline

Innate and Adaptive Immune Systems

Page 9: Discussion Outline

Antigen Presentation

Page 10: Discussion Outline

Adaptive Immunity

Page 11: Discussion Outline

Function of the Immune System

Page 12: Discussion Outline

Tumor Escape Mechanisms

Page 13: Discussion Outline

Risk for Malignancies Is Higher in Immunosuppressed Patients With Organ Transplants Compared With in Healthy

Individuals*

Page 14: Discussion Outline

Cancer and Immunoediting

Page 15: Discussion Outline

Antigen Presentation and T-Cell Priming

Page 16: Discussion Outline

Reasons for Failed Vaccine Studies

Page 17: Discussion Outline

Tumor Antigens

Page 18: Discussion Outline

Dual Role of the Immune System in Cancer

Page 19: Discussion Outline

Chimeric Antigen-Receptor T Cells for Lymphoma

Page 20: Discussion Outline

Multiple Costimulatory and Inhibitory Interactions Regulate T-Cell Responses

Page 21: Discussion Outline

CTLA-4: Negatively Modulates the Immune Response

Page 22: Discussion Outline

Phase 3 Trial of Ipilimumab in Melanoma

Page 23: Discussion Outline

Progression-Free Survival in Patients Receiving Ipilimumab for

Lung Cancer

Page 24: Discussion Outline

Immune Checkpoints Regulate the Immune System

Page 25: Discussion Outline

Phase 1 Study: Activity of Nivolumab

Page 26: Discussion Outline

Targeted Agents Against Immune Checkpoint Pathways

Page 27: Discussion Outline

Antibodies to Tumor-Expressing Antigens

Page 28: Discussion Outline

Measuring Response With Immune Therapies

Page 29: Discussion Outline

Future Objectives

Page 30: Discussion Outline

Nivolumab + Ipilimumab in Patients With Advanced Melanoma

Page 31: Discussion Outline

Combination Studies of Checkpoint Inhibitors

Page 32: Discussion Outline

Conclusions

Page 33: Discussion Outline

Abbreviations

Page 34: Discussion Outline

Abbreviations (cont)

Page 35: Discussion Outline

Abbreviations (cont)

Page 36: Discussion Outline

References

Page 37: Discussion Outline

References (cont)

Page 38: Discussion Outline

References (cont)

Page 39: Discussion Outline

References (cont)

Page 40: Discussion Outline

References (cont)

Page 41: Discussion Outline

References (cont)

Page 42: Discussion Outline

References (cont)

Page 43: Discussion Outline

References (cont)

Page 44: Discussion Outline

References (cont)

Page 45: Discussion Outline

References (cont)

Page 46: Discussion Outline

References (cont)

Page 47: Discussion Outline

References (cont)